BioMarin seeks UK approval to begin trial of Batten disease drug

04/3/2013 | Pharmaceutical Business Review Online

BioMarin Pharmaceutical filed an application with the U.K. Medicines and Healthcare Products Regulatory Agency seeking approval to initiate a Phase I/II trial of BMN-190, an experimental drug for neuronal ceroid lipofuscinosis type 2, a form of Batten disease. The firm expects patient enrollment for the trial to begin this year.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA